Gözde Korkmaz obtained her Bachelor’s degree in Molecular Biology and Genetics from Istanbul Technical University. She received her PhD degree from Sabancı University, Department of Biological Sciences and Bioengineering, in 2012. She conducted her post-doctoral studies at Reuven Agami's laboratory at the Netherlands Cancer Institute. In 2020, she joined Koç University, School of Medicine, as an assistant professor and started her own lab. She is a recipient of the TÜBİTAK 2232 International Fellowship for Outstanding Researchers Program and received the Bilim Akademisi-BAGEP and Turkish Academy of Science-GEBİP award in 2021.
Our research revolves around transcriptional regulation and epigenetics and their role in cancer development and drug resistance. Techniques based on CRISPR (such as genome-scale CRISPR-Cas9 screens) are combined with next-generation sequencing to identify new therapeutic targets in cancer.
Gözde Korkmaz obtained her Bachelor’s degree in Molecular Biology and Genetics from Istanbul Technical University. She received her PhD degree from Sabancı University, Department of Biological Sciences and Bioengineering, in 2012. She conducted her post-doctoral studies at Reuven Agami's laboratory at the Netherlands Cancer Institute. In 2020, she joined Koç University, School of Medicine, as an assistant professor and started her own lab. She is a recipient of the TÜBİTAK 2232 International Fellowship for Outstanding Researchers Program and received the Bilim Akademisi-BAGEP and Turkish Academy of Science-GEBİP award in 2021.
Our research revolves around transcriptional regulation and epigenetics and their role in cancer development and drug resistance. Techniques based on CRISPR (such as genome-scale CRISPR-Cas9 screens) are combined with next-generation sequencing to identify new therapeutic targets in cancer.